Defining quality indicators for best-practice management of inflammatory bowel disease in Canada

Canadian Journal of Gastroenterology and Hepatology

Volumn 28, Issue 5, 2014, Pages 275-285

  Nguyen, Geoffrey C ^a   Devlin, Shane M ^b   Afif, Waqqas ^c   Bressler, Brian ^d   Gruchy, Steven E ^e   Kaplan, Gilaad G ^b   Oliveira, Liliana ^f   Plamondon, Sophie ^g   Seow, Cynthia H ^b   Williams, Chadwick ^h   Wong, Karen ⁱ   Yan, Brian M ^j   Jones, Jennifer ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h SAINT JOHN REGIONAL HOSPITAL   (Canada)

ⁱ Mount Saint Joseph Hospital   (Canada)

^j UNIVERSITY OF WESTERN ONTARIO   (Canada)

^k UNIVERSITY OF SASKATCHEWAN   (Canada)

more..

Author keywords

Canada; Crohn disease; Delivery of health care; Process assessment; Quality indicators; Ulcerative colitis

Indexed keywords

FONDAPARINUX; HEPARIN;

CANADA; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINE; STANDARDS;

CANADA; HUMANS; INFLAMMATORY BOWEL DISEASES; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 84902659142     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2014/941245     Document Type: Review

References (161)

1. Crohn's and Colitis Foundation of Canada. The Impact of Inflammatory Bowel Disease in Canada: 2012 Final Report and Recommendations. Toronto: Crohn's and Colitis Foundation of Canada, 2012. 〈www.isupportibd.ca〉 (Accessed June 2013).
2. Canadian Council on Health Services Accreditation. A Guide to the Development and Use of Performance Indicators. Ottawa: Canadian Council on Health Services Accreditation, 1996.
3. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003;15:523-30. (Pubitemid 37540789)
4. Malenka DJ, O'Connor GT. The Northern New England Cardiovascular Disease Study Group: A regional collaborative effort for continuous quality improvement in cardiovascular disease. J Comm J Qual Improv 1998;24:594-600.
5. Quon BS, Goss CH. A story of success: Continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011;66:1106-8.
6. American Gastroenterological Association. Adult Inflammatory Bowel Disease Physician Performance Measures Set: American Gastroenterological Association, 2011. 〈www.ama-assn.org/resources/doc/pcpi/inflammatory-bowel- disease.pdf〉 (Accessed June 17, 2013).
7. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: Development of process and outcome measures. Inflamm Bowel Dis 2013;19:662-8.
8. Kappelman MD. IBD standards: Will they enhance patient care? In: Irving P, Siegel C, Rampton D, Shanahan F, eds. Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges. Chichester: Wiley-Blackwell, 2011.
9. Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: The risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:953-62.
10. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study. Lancet 2010;375:657-63.
11. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272-80.
12. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007;21:507-11. (Pubitemid 47532873)
13. Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: The medical inpatients and thrombosis (MITH) study. J Thromb Haemost 2013;11:634-41.
14. Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: Are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012;55:1138-44.
15. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: A study of National Surgical Quality Improvement Program patients. Arch Surg 2012;147:120-4.
16. Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 2013;58:46-52.
17. Razik R, Bernstein CN, Sam J, Thanabalan R, Nguyen GC. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol 2012;26:795-8.
18. Baser O, Liu X, Phatak H, et al. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther 2013;20:132-42.
19. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195S-226S.
20. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: Special situations. J Crohns Colitis 2013;7:1-33.
21. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107:179-94.
22. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
23. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23.
24. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010;4:63-101.
25. Ra G, Thanabalan R, Ratneswaran S, Nguyen GC. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis 2013;7:e479-85.
26. Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007;26:653-63. (Pubitemid 47246205)
27. Collaboration CT, Dennis M, Sandercock P, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): A multicentre randomised controlled trial. Lancet 2013;382:516-24.
28. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50. (Pubitemid 351813903)
29. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44. (Pubitemid 46401530)
30. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: An assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-9.
31. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:976-83.
32. Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis 2009;3:4-7.
33. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:1322-31.
34. Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012;36:1032-9.
35. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis 2012;6:330-6.
36. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415-20.
37. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009;15:3504-10.
38. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-7. (Pubitemid 36363410)
39. Nunes T, Etchevers MJ, Merino O, et al. Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis 2013;19:23-9.
40. Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol 2005;39:32-5. (Pubitemid 40041340)
41. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: A meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213-21.
42. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004;187:219-25. (Pubitemid 38183436)
43. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8. (Pubitemid 24064330)
44. Johnson GJ, Cosnes J, Mansfield JC. Review article: Smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921-31. (Pubitemid 40529727)
45. Marshall JK. Reporting ileocolonoscopy in inflammatory bowel disease. Can J Gastroenterol 2006;20:399-400. (Pubitemid 44083427)
46. de Lange T, Moum BA, Tholfsen JK, Larsen S, Aabakken L. Standardization and quality of endoscopy text reports in ulcerative colitis. Endoscopy 2003;35:835-40. (Pubitemid 37254217)
47. Leighton JA, Shen B, Baron TH, et al. ASGE guideline: Endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006;63:558-65.
48. Armstrong D, Barkun A, Bridges R, et al. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol 2012;26:17-31.
49. Beaulieu D, Barkun AN, Dube C, et al. Endoscopy reporting standards. Can J Gastroenterol 2013;27:286-92.
50. Leddin D, Bridges RJ, Morgan DG, et al. Survey of access to gastroenterology in Canada: The SAGE wait times program. Can J Gastroenterol 2010;24:20-5.
51. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010:CD000545.
52. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 7;(4):CD000545. (Review. Update in: 2010;(6):CD000545 CD000067).
53. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
54. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32. (Pubitemid 30341531)
55. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
56. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
57. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61.
58. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33.
59. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
60. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
61. Bultman E, Kuipers EJ, van der Woude CJ. Systematic review: Steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:313-23.
62. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73. (Pubitemid 46454266)
63. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. Br Med J 1974;4:627-30.
64. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9.
65. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982;284:1291-2. (Pubitemid 12150320)
66. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53. (Pubitemid 41820634)
67. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122-8. (Pubitemid 38917818)
68. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: One-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19:14-6. (Pubitemid 30048938)
69. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-33.
70. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. ECCO 2013:Abstract 13.
71. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21. (Pubitemid 26134073)
72. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
73. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
74. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011;60:780-7.
75. Van Assche G, Wolf D, D'Haens G, et al. Reduced steroid usage in ulcerative colitis patients with week 8 response to adalimumab: Subanalysis of ULTRA 2. Gut 2012;61(Suppl 3):A81. Abstract OP350.
76. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
77. Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients. Inflamm Bowel Dis 2010;16:1912-21.
78. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1308-19.
79. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012;18:1057-63.
80. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. (Pubitemid 38447195)
81. Menzies D, Pai M, Comstock G. Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54. (Pubitemid 351650594)
82. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:2034-42.
83. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-gamma assay results for tuberculosis and boosting effect of tuberculin skin testing: A systematic review. PLoS One 2009;4:e8517.
84. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008;34:1-13.
85. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39. (Pubitemid 47031141)
86. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83.
87. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
88. Sadowski DC, Bernstein CN, Bitton A, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202.
89. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: Analysis of 257 cases. Medicine (Baltimore) 2011;90:359-71.
90. Travis SP, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008;2:24-62. (Pubitemid 351179488)
91. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10. (Pubitemid 46096828)
92. Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7.
93. de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:972-80.
94. Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97:404-9.
95. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10. (Pubitemid 26231777)
96. Manosa M, Cabre E, Garcia-Planella E, et al. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. Inflamm Bowel Dis 2011;17:2497-502.
97. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
98. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-6.
99. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483-90. (Pubitemid 29075187)
100. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33. (Pubitemid 27093099)
101. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-403.
102. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995;5:156-60.
103. Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 2011;17:2122-9.
104. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997;40:313-9. (Pubitemid 27145642)
105. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795-841. (Pubitemid 36268496)
106. American Gastroenterological Association medical position statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:791-4.
107. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:797-813. (Pubitemid 44253764)
108. Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease: British Society of Gastroenterology, 2007. 〈www.bsg.org.uk〉 (Accessed June 17, 2013).
109. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001;91:854-62. (Pubitemid 32173312)
110. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. (Pubitemid 20366527)
111. Jess T, Loftus EV, Jr., Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from Olmsted County, Minnesota. Gastroenterology 2006;130:1039-46.
112. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
113. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centres. Gut 1988;29:206-17. (Pubitemid 18078890)
114. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2. (Pubitemid 24339258)
115. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526-35. (Pubitemid 32234798)
116. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-81.
117. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8. (Pubitemid 26043863)
118. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522-5.
119. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: Results from a 20-year surveillance study. Dis Colon Rectum 2001;44:77-85. (Pubitemid 32105878)
120. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285-8. (Pubitemid 27328584)
121. Braden B, Halliday J, Aryasingha S, et al. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012;10:303-8.
122. Nuako KW, Ahlquist DA, Sandborn WJ, et al. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: A case-control study. Cancer 1998;82:822-6. (Pubitemid 28104159)
123. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9:52-6.
124. Brostrom O, Lofberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: A clinical, endoscopical, and histological study. Gut 1986;27:1408-13. (Pubitemid 17218506)
125. Leidenius M, Kellokumpu I, Husa A, Riihela M, Sipponen P. Dysplasia and carcinoma in longstanding ulcerative colitis: An endoscopic and histological surveillance programme. Gut 1991;32:1521-5.
126. Lindberg J, Stenling R, Palmqvist R, Rutegard J. Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 26 years' experience in a patient cohort from a defined population area. Scand J Gastroenterol 2005;40:1076-80. (Pubitemid 41291357)
127. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-8.
128. Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418-24. (Pubitemid 23213526)
129. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;19;(2):CD000279.
130. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-6. (Pubitemid 32193178)
131. Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: Results of a 23-year surveillance programme in the Japanese population. Br J Cancer 2003;89:1232-6. (Pubitemid 37363409)
132. Riegler G, Bossa F, Caserta L, et al. Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. A retrospective co-operative IG-IBD study. Dig Liver Dis 2003;35:628-34. (Pubitemid 41110873)
133. Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995;108:1361-70.
134. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009;104:2222-32.
135. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(Suppl 5):v10-2. (Pubitemid 35222898)
136. Leddin D, Hunt R, Champion M, et al. Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. Can J Gastroenterol 2004;18:93-9. (Pubitemid 38418034)
137. Leighton JA, Shen B, Baron TH, et al. ASGE guideline: Endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006;63:558-65.
138. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738-45.
139. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-21. (Pubitemid 40439686)
140. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
141. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-50.
142. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial. Gastroenterology 2008;135:1123-9.
143. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: Evidence for two clinical forms. Gut 1988;29:588-92.
144. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72. (Pubitemid 14122134)
145. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63. (Pubitemid 20338451)
146. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: Endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-5.
147. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63.
148. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677-92. (Pubitemid 39276481)
149. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
150. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834-40. (Pubitemid 44166594)
151. Wilckens V, Kannengiesser K, Hoxhold K, et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol 2011;46:855-61.
152. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148-54.
153. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study. Inflamm Bowel Dis 2012;18:1042-7.
154. Gelinck LB, van der Bijl AE, Visser LG, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008;26:3528-33.
155. Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011;63:3723-32.
156. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-6. (Pubitemid 47031059)
157. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444-53.
158. deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25-33.
159. Romanowska M, Banaszkiewicz A, Nowak I, Radzikowski A, Brydak LB. Immunization against influenza during the 2005/2006 epidemic season and the humoral response in children with diagnosed inflammatory bowel disease (IBD). Med Sci Monit 2010;16:CR433-9.
160. Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: Effects of combined therapy with immunosuppressants. J Crohns Colitis 2013;7:301-7.
161. Crandall WV, Margolis PA, Kappelman MD, et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics 2012;129:e1030-41.